Citigroup Maintains Neutral on Integra Lifesciences, Lowers Price Target to $59
Citigroup analyst Joanne Wuensch maintains Integra Lifesciences (NASDAQ:IART) with a Neutral and lowers the price target from $60 to $59.
Integra LifeSciences Expects FY23 Revenues Of $1.60B-$1.62B Vs. Consensus Of $1.62B, Adjusted EPS Of $3.43-$3.51 Vs. $3.52 Estimate
The guidance reflects a sequential improvement from first to second-half growth primarily driven by the gradual recovery of supply throughout the year, 2022 normalization from private label business, the recovery of
Earnings Scheduled For February 22, 2023
Companies Reporting Before The Bell
• Rio Tinto (NYSE:RIO) is projected to report earnings for its Fiscal Year 2022.
Morgan Stanley Maintains Equal-Weight on Integra Lifesciences, Raises Price Target to $59
Morgan Stanley analyst Drew Ranieri maintains Integra Lifesciences (NASDAQ:IART) with a Equal-Weight and raises the price target from $50 to $59.
Truist Securities Maintains Hold on Integra Lifesciences, Raises Price Target to $58
Truist Securities analyst Richard Newitter maintains Integra Lifesciences (NASDAQ:IART) with a Hold and raises the price target from $52 to $58.
Integra LifeSciences Shares Surge On Q3 Beat
Integra LifeSciences Holdings Corp (NASDAQ:IART) reported Q3 FY22 sales of $385.19 million, -0.4% Y/Y on a reported basis, and +3.5% organic,…
Integra Lifesciences Increases Guidance
Integra Lifesciences Holdings Corp (NASDAQ:IART) reaffirmed FY22 revenue guidance at the midpoint of its August 2022 guidance of $1.551 billion - $1.563 billion with an estimate of $1.57 billion. It raised FY22 adj EPS
4 Analysts Have This to Say About Integra Lifesciences
Over the past 3 months, 4 analysts have published their opinion on Integra Lifesciences (NASDAQ:IART) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.
